Detection of Second Primary Lymphoma in Late Diffuse Large B-cell Lymphoma Recurrences
| Autor: | Madeleine R. Berendsen, Diede A.G. van Bladel, Eva Hesius, Fleur A. de Groot, Leonie I. Kroeze, Jos Rijntjes, Jeroen A.C.W. Luijks, Brigiet Hoevenaars, Altuna Halilovic, Peet Nooijen, Esther van Bladel, Susan de Jonge-Peeters, Chantal Lensen, Hans Pruijt, Ellen van der Spek, Joost S.P. Vermaat, Corine Hess, Konnie M. Hebeda, Wendy B.C. Stevens, J. Han J.M. van Krieken, Michiel van den Brand, Patricia J.T.A. Groenen, Blanca Scheijen |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
immunoglobulin gene
relapse All institutes and research themes of the Radboud University Medical Center clonality analysis Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] diffuse large B-cell lymphoma rearrangements Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] second primary lymphoma Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] Pathology and Forensic Medicine |
| Zdroj: | Modern Pathology, 36 Modern Pathology, 36(5). ELSEVIER SCIENCE INC Modern Pathology, 36, 5 |
| ISSN: | 0893-3952 |
| Popis: | Approximately one-third of patients with diffuse large B-cell lymphoma (DLBCL) relapse and often require salvage chemotherapy followed by autologous stem cell transplantation. In most cases, the clonal relationship between the first diagnosis and subsequent relapse is not assessed, thereby potentially missing the identification of second primary lymphoma. In this study, the clonal rela-tionship of 59 paired DLBCL diagnoses and recurrences was established by next-generation sequencing-based detection of immunoglobulin gene rearrangements. Among 50 patients with interpretable results, 43 patients (86%) developed clonally related relapsed disease. This was observed in 100% of early recurrences (= 5 years). On the other hand, 7 (14%) out of 50 patients displayed different dominant clonotypes in primary DLBCL and clinical recurrences, confirming the occurrence of second primary DLBCL; 37% of DLBCL recurrences that occurred >= 4 years after diagnosis were shown to be second primary lymphomas. The clonally unrelated cases were Epstein-Barr virus positive in 43% of the cases, whereas this was only 5% in the relapsed DLBCL cases. In conclusion, next-generation sequencing-based clonality testing in late recurrences should be considered in routine diagnostics to distinguish relapse from second primary lymphoma, as this latter group of patients with DLBCL may benefit from less-intensive treatment strategies.(c) 2023 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology. This is an open access article under the CC BY license (http://creativecommons.org/ licenses/by/4.0/). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|